Dramatic and promising responses to agents like bevacizumab [29], sunitinib [30], and sorafenib [31] have also been reported, and their efficacy may be linked to the enhanced VEGF production in most cases of angiosarcoma [12, 32]. This evidence concerns the gene VEGFA and angiosarcoma.